We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+4.02%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$14.7B
AUM Growth
-$14.5M
Cap. Flow
+$16.2M
Cap. Flow %
0.11%
Top 10 Hldgs %
85.95%
Holding
111
New
8
Increased
15
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$115M
2
IGMS
IGM Biosciences
IGMS
+$63.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$47.4M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$26.6M
5
URGN icon
UroGen Pharma
URGN
+$24.4M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$132M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$113M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$6.49M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.15M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 99.6%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$4.27B 29.08%
50,057,277
– –
INCY icon
2
Incyte
INCY
$25.9B
$2.37B 16.15%
31,976,557
+364
+0% +$29.4K
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$5.08B
$1.47B 10%
40,854,586
+1,562,500
+4% +$47.4M
ONC
4
BeOne Medicines Ltd
ONC
$42.4B
$1.44B 9.81%
11,777,285
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$809M 5.5%
8,258,068
– –
AMRN
6
Amarin Corp
AMRN
$298M
$630M 4.28%
2,077,214
– –
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$627M 4.27%
9,244,665
-16,257
-0.2% -$1.12M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12.9B
$512M 3.48%
7,589,294
– –
ASND icon
9
Ascendis Pharma A/S
ASND
$16.6B
$327M 2.22%
3,390,270
– –
NVTA
10
DELISTED
Invitae Corporation
NVTA
$169M 1.15%
8,792,678
+4,890,257
+125% +$115M
KOD icon
11
Kodiak Sciences
KOD
$2.41B
$132M 0.89%
9,145,116
+1
+0% +$13
NBIX icon
12
Neurocrine Biosciences
NBIX
$15.5B
$128M 0.87%
1,415,283
– –
ARGX icon
13
argenx
ARGX
$65B
$116M 0.79%
1,019,557
– –
HRTX icon
14
Heron Therapeutics
HRTX
$60.4M
$111M 0.76%
6,018,104
– –
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$102M 0.69%
1,307,220
-1,206,242
-48% -$113M
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$11.9B
$101M 0.69%
1,169,278
– –
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$79.1M 0.54%
1,517,237
+500,931
+49% +$26.6M
ONCE
18
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$72.9M 0.5%
751,927
– –
TCDA
19
DELISTED
Tricida, Inc. Common Stock
TCDA
$60.8M 0.41%
1,969,905
– –
RYTM icon
20
Rhythm Pharmaceuticals
RYTM
$7.57B
$58.5M 0.4%
2,708,200
– –
IGMS
21
DELISTED
IGM Biosciences
IGMS
$55.8M 0.38%
+3,144,000
New +$63.5M
RARX
22
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$55.5M 0.38%
2,345,496
+543,801
+30% +$16.1M
CERS icon
23
Cerus
CERS
$566M
$55.4M 0.38%
10,749,937
– –
DBVT
24
DBV Technologies
DBVT
$914M
$47.4M 0.32%
550,956
– –
PRNB
25
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$46.7M 0.32%
1,654,029
-133,778
-7% -$4.91M
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2019 Portfolio in Review

As of Q3 2019, Julian Baker held 111 positions worth $14.7B, down 0.1% from $14.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q3 2019 filing shows 8 new, 15 increased, 6 reduced and 2 closed positions. Its largest new stake was IGM Biosciences: 3,144,000 shares worth $55.8M. The largest sale was Array Biopharma Inc, an estimated $132M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Technology.

  • Julian Baker's largest Q3 2019 buy was IGM Biosciences: 3,144,000 shares worth $55.8M.
  • Julian Baker added most to Invitae Corporation in Q3 2019, an estimated $115M increase.
  • Julian Baker's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $113M.
  • Julian Baker fully exited Array Biopharma Inc in Q3 2019, selling an estimated $132M.
  • Julian Baker's ten largest holdings make up 86% of its $14.7B portfolio in Q3 2019.
  • Julian Baker opened 8 new positions and closed 2 in Q3 2019.
  • Julian Baker's portfolio value fell 0.1% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.